adplus-dvertising
Connect with us

Business

Coronavirus: Health Canada approves two AstraZeneca COVID-19 vaccines – CTV News

Published

 on


TORONTO —
Health Canada has approved the Oxford-AstraZeneca COVID-19 vaccine and a related shot by the Serum Institute of India for use in this country with the first doses expected to arrive soon.

Canada joins more than a dozen other countries that have given the green light to ChAdOx1 nCoV-19, the shot from AstraZeneca and Oxford University, which was among the first buzzed-about vaccine candidates in 2020.

A version of the AstraZeneca vaccine by the Indian pharmaceutical company Serum Institute of India and sponsored by Verity Pharmaceuticals Inc. in Canada has also been approved for use and is considered a separate vaccine by Health Canada.

The two-dose vaccines have been approved for use in people 18 years of age and older, including seniors, with the recommendation that the second dose be administered between four and 12 weeks after the first, officials said Friday.

“This is very encouraging news. It means more people vaccinated and sooner,” said Prime Minister Justin Trudeau at a press conference on Friday.

“We’re ready to get doses rolling… With Pfizer, Moderna and now AstraZeneca, Canada will get to more than 6.5 million doses by the end of March.”​

Shipments of the newly approved vaccines will amount to about 24 million doses between April and September. AstraZeneca has promised to ship 20 million doses to Canada from the U.S., with the federal government saying it’s been in talks with AstraZeneca about locking in shipments as soon as the regulatory green light was given. A timeline for the U.S. shipments has not been provided.

Another two million doses will come from the Serum Institute of India, with the first 500,000 expected by the end of March.

As well, officials anticipate 1.9 million doses as part of the global vaccine-sharing program known as COVAX. Advocates for poorer countries have criticized this shipment, saying Canada has procured enough doses through private deals. An initial COVAX batch of 500,000 doses is set to arrive in Canada from South Korea before April.

The inoculants, which are the third and fourth approved COVID-19 vaccines in Canada, is considered to be relatively cheap and easy-to-store, a factor that sets it apart from the Pfizer-BioNTech and Moderna vaccines already in circulation. AstraZeneca has reached agreements with international health bodies and governments to price each dose at about US$2.50. Doses of the AstraZeneca shot can be stored at temperatures between 2 C to 8 C, while the other two require ultra-cold freezers.

“The big, big thing that makes this different than other vaccines, which is a huge, huge advantage, is that it can be stored at refrigeration temperature,” Dr. Zain Chagla, an infectious disease specialist and associate professor at McMaster University, told CTV News Channel on Friday. 

“For a vaccine rollout to go to remote areas, to go to homeless shelters, to go to places that can’t tolerate even a -20 C fridge, this is going to be an incredible tool.”

The newly approved vaccines are the first “viral vector-based vaccines” for COVID-19 to be approved in Canada. This type of vaccine, which uses a modified cold virus commonly found in chimpanzees, has been in use for decades, said Health Canada’s chief medical adviser, Dr. Supriya Sharma, on Friday.

Viral vector vaccines use a “harmless modified version of a different virus — the vector — to deliver instructions to our cells,” she said. “The cells begin to mark proteins from the virus that causes COVID-19, which then prompts the body to develop an immune response.”

The Pfizer and Moderna shots are both messenger RNA technology, which provide a kind of “instruction booklet” for cells to make antigens.

EFFICACY CONCERNS

The AstraZeneca vaccine has already faced efficacy concerns as variants of the novel coronavirus pop up around the world. In South Africa, officials suspended plans to use the shot on health-care workers after a clinical trial indicated it is less effective against the B.1.351 variant predominant in that country.

In France, the vaccine is only being administered to people under the age of 65, as officials cited a lack of data about its efficacy for older people. While Health Canada acknowledged Friday that the clinical trial data was limited for seniors, officials said blood tests showed people over 65 still produced COVID-19 antibodies after vaccination. Plus, the “real world evidence and post-market experience” in countries that have been using the AstraZeneca vaccine showed “a potential benefit and no safety concerns” in seniors.

CTV News Infectious Disease Specialist Dr. Abdu Sharkawy said people concerned about the efficacy of the AstraZeneca vaccines should look to a regular flu season for some “perspective.”

“A great match between a circulating flu strain and the vaccine in a given year might not exceed 60 per cent. If the flu vaccine is delivered widely in the community, we see dramatic reduction in every bad outcome,” he told CTV News Channel on Friday.

“This [AstraZeneca trial] was a multinational trial in five countries and there wasn’t a single death or a single episode of really severe disease really attributable to the vaccine, [which] did a great job in reducing both of those very important metrics. 

While federal health regulators received the application for authorization from Verity and Serum Institute on Jan. 23, they were reviewing the AstraZeneca vaccine for nearly five months in collaboration with the European Medicines Agency. In early February, health officials said they were going back and forth with AstraZeneca about what information the vaccine label will include and cited ongoing trials in the U.S. as one of the reasons the review process for the jab had been “complicated.”

With files from The Canadian Press and CTV’s Rachel Aiello 

Let’s block ads! (Why?)

728x90x4

Source link

Continue Reading

Business

Roots sees room for expansion in activewear, reports $5.2M Q2 loss and sales drop

Published

 on

 

TORONTO – Roots Corp. may have built its brand on all things comfy and cosy, but its CEO says activewear is now “really becoming a core part” of the brand.

The category, which at Roots spans leggings, tracksuits, sports bras and bike shorts, has seen such sustained double-digit growth that Meghan Roach plans to make it a key part of the business’ future.

“It’s an area … you will see us continue to expand upon,” she told analysts on a Friday call.

The Toronto-based retailer’s push into activewear has taken shape over many years and included several turns as the official designer and supplier of Team Canada’s Olympic uniform.

But consumers have had plenty of choice when it comes to workout gear and other apparel suited to their sporting needs. On top of the slew of athletic brands like Nike and Adidas, shoppers have also gravitated toward Lululemon Athletica Inc., Alo and Vuori, ramping up competition in the activewear category.

Roach feels Roots’ toehold in the category stems from the fit, feel and following its merchandise has cultivated.

“Our product really resonates with (shoppers) because you can wear it through multiple different use cases and occasions,” she said.

“We’ve been seeing customers come back again and again for some of these core products in our activewear collection.”

Her remarks came the same day as Roots revealed it lost $5.2 million in its latest quarter compared with a loss of $5.3 million in the same quarter last year.

The company said the second-quarter loss amounted to 13 cents per diluted share for the quarter ended Aug. 3, the same as a year earlier.

In presenting the results, Roach reminded analysts that the first half of the year is usually “seasonally small,” representing just 30 per cent of the company’s annual sales.

Sales for the second quarter totalled $47.7 million, down from $49.4 million in the same quarter last year.

The move lower came as direct-to-consumer sales amounted to $36.4 million, down from $37.1 million a year earlier, as comparable sales edged down 0.2 per cent.

The numbers reflect the fact that Roots continued to grapple with inventory challenges in the company’s Cooper fleece line that first cropped up in its previous quarter.

Roots recently began to use artificial intelligence to assist with daily inventory replenishments and said more tools helping with allocation will go live in the next quarter.

Beyond that time period, the company intends to keep exploring AI and renovate more of its stores.

It will also re-evaluate its design ranks.

Roots announced Friday that chief product officer Karuna Scheinfeld has stepped down.

Rather than fill the role, the company plans to hire senior level design talent with international experience in the outdoor and activewear sectors who will take on tasks previously done by the chief product officer.

This report by The Canadian Press was first published Sept. 13, 2024.

Companies in this story: (TSX:ROOT)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Talks on today over HandyDART strike affecting vulnerable people in Metro Vancouver

Published

 on

 

VANCOUVER – Mediated talks between the union representing HandyDART workers in Metro Vancouver and its employer, Transdev, are set to resume today as a strike that has stopped most services drags into a second week.

No timeline has been set for the length of the negotiations, but Joe McCann, president of the Amalgamated Transit Union Local 1724, says they are willing to stay there as long as it takes, even if talks drag on all night.

About 600 employees of the door-to-door transit service for people unable to navigate the conventional transit system have been on strike since last Tuesday, pausing service for all but essential medical trips.

Hundreds of drivers rallied outside TransLink’s head office earlier this week, calling for the transportation provider to intervene in the dispute with Transdev, which was contracted to oversee HandyDART service.

Transdev said earlier this week that it will provide a reply to the union’s latest proposal on Thursday.

A statement from the company said it “strongly believes” that their employees deserve fair wages, and that a fair contract “must balance the needs of their employees, clients and taxpayers.”

This report by The Canadian Press was first published Sept. 12, 2024.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Transat AT reports $39.9M Q3 loss compared with $57.3M profit a year earlier

Published

 on

 

MONTREAL – Travel company Transat AT Inc. reported a loss in its latest quarter compared with a profit a year earlier as its revenue edged lower.

The parent company of Air Transat says it lost $39.9 million or $1.03 per diluted share in its quarter ended July 31.

The result compared with a profit of $57.3 million or $1.49 per diluted share a year earlier.

Revenue in what was the company’s third quarter totalled $736.2 million, down from $746.3 million in the same quarter last year.

On an adjusted basis, Transat says it lost $1.10 per share in its latest quarter compared with an adjusted profit of $1.10 per share a year earlier.

Transat chief executive Annick Guérard says demand for leisure travel remains healthy, as evidenced by higher traffic, but consumers are increasingly price conscious given the current economic uncertainty.

This report by The Canadian Press was first published Sept. 12, 2024.

Companies in this story: (TSX:TRZ)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending